Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$4.99M
• Dividend Yield: N/A
• Average Volume (3M): 112.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 166,233,230
• 10 Day Avg. Volume: 120,057
• 30 Day Avg. Volume: 112,955
• PEG Ratio: 0.13
• Price to Book (P/B): -9.04
• Price to Sales (P/S): 7.08
• P/FCF Ratio: -3.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Kane Biotech's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, persistent losses, high leverage, and cash flow constraints. Technical analysis shows a bearish trend with some potential for reversal, but valuation metrics remain unattractive due to ongoing losses and lack of profitability. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Innovative Product Line

Kane Biotech's focus on antimicrobial products addresses critical biofilm-related challenges, positioning it well in healthcare and consumer markets.

Strategic Partnerships

Strategic partnerships in healthcare enhance distribution capabilities, potentially increasing market reach and revenue stability.

Licensing Revenue Stream

Licensing agreements offer a steady revenue stream, diversifying income sources and reducing reliance on direct sales.

Negative Factors

Declining Revenue

Declining revenue growth indicates challenges in market demand or competitive positioning, impacting long-term financial health.

High Leverage

High leverage increases financial risk, limiting flexibility and potentially affecting the company's ability to invest in growth.

Cash Flow Constraints

Cash flow constraints hinder the company's ability to fund operations and invest in growth, posing a risk to sustainability.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

How the Company Makes Money

Kane Biotech generates revenue through multiple streams, including the sale of its proprietary antimicrobial products to healthcare providers, veterinary clinics, and industrial clients. The company also engages in licensing agreements, allowing other manufacturers to use its technology in their products, which provides a steady royalty income. Additionally, Kane Biotech may partner with larger pharmaceutical or medical device companies for collaborative research and development projects, which can lead to milestone payments and shared revenue from resulting products. The company’s focus on addressing biofilm-related issues positions it to capitalize on growing market demand in both healthcare and industrial applications.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing significant financial challenges. The income statement shows declining revenue and persistent losses, the balance sheet reflects high leverage and negative equity, and the cash flow statement indicates cash flow constraints. The company needs to address its operational inefficiencies and financial instability to improve its financial health and sustainability.

Income Statement

Kane Biotech's income statement reveals significant challenges. The company has experienced a substantial decline in revenue growth, with a negative growth rate of -24.27% in the TTM period. Profitability metrics are concerning, with a negative net profit margin of -105.22% and negative EBIT and EBITDA margins, indicating ongoing operational losses. The gross profit margin has also decreased from previous periods, reflecting pressure on cost management. Overall, the income statement highlights severe profitability issues and declining revenue trends.

Balance Sheet

The balance sheet of Kane Biotech shows financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -11.09 in the TTM period, indicating high leverage and financial risk. The return on equity is positive but misleading due to negative equity. The equity ratio is not calculable due to negative equity, further emphasizing the company's weak financial position. Overall, the balance sheet reflects high leverage and financial distress.

Cash Flow

Kane Biotech's cash flow statement indicates cash flow challenges. The free cash flow growth rate is negative at -31.93% in the TTM period, showing a decline in cash generation. The operating cash flow to net income ratio is negative, reflecting insufficient cash flow to cover net losses. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is marginally covering net losses. Overall, the cash flow statement highlights cash flow constraints and operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.85M	2.08M	148.98K	156.73K	1.61M	1.34M
Gross Profit	468.47K	872.10K	109.47K	1.41M	568.44K	526.86K
EBITDA	-2.83M	-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
Net Income	-1.95M	-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet
Total Assets	3.81M	2.49M	5.68M	5.62M	6.13M	5.04M
Cash, Cash Equivalents and Short-Term Investments	1.61M	358.81K	749.25K	1.10M	1.15M	1.01M
Total Debt	2.61M	2.29M	9.26M	6.86M	4.71M	2.25M
Total Liabilities	4.05M	4.12M	14.09M	9.76M	7.70M	3.96M
Stockholders Equity	-234.99K	-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow
Free Cash Flow	-2.94M	-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
Operating Cash Flow	-2.83M	-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
Investing Cash Flow	-62.50K	10.27M	-116.14K	-107.55K	-373.55K	-166.11K
Financing Cash Flow	3.50M	-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$14.60M	―	―	―	-3.93%	-575.24%
HEM	41 Neutral	C$17.48M	-3.24	―	―	―	-28.51%
KNE	41 Neutral	C$4.99M	-2.19	―	―	―	―
BETR	21 Underperform	C$8.35M	―	―	―	―	85.61%

Kane Biotech Corporate Events

Kane Biotech’s revyve Gel Shows Promising Results in Wound Care

Kane Biotech recently presented promising clinical and pre-clinical data for its revyve Antimicrobial Wound Gel and Gel Spray at major U.S. medical conferences. The data showed significant improvements in diabetic foot ulcer healing and burn wound infection control, with the revyve products outperforming the standard of care by achieving a 97% reduction in wound area within four weeks and complete closure within 12 weeks. These findings highlight revyve’s potential to enhance wound care outcomes and support Kane Biotech’s strategy to impact the U.S. wound care market.

Kane Biotech’s New Acne Treatment Study: What Investors Need to Know

Kane Biotech Inc., in collaboration with the University of Miami, is launching a clinical study titled ‘Split-face Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris.’ The study aims to evaluate the effectiveness and tolerability of DispersinB Acne Cleanser in treating facial acne. The primary objectives include assessing the percentage of subjects rated as ‘Clear’ or ‘Almost Clear’ and changes in lesion count after 12 weeks of treatment.

Kane Biotech Submits FDA Clearance for New Wound Cleanser

Kane Biotech has submitted a 510(k) clearance to the U.S. FDA for its new revyve Antimicrobial Wound Cleanser, expanding its revyve product line. This product is designed to aid in wound management by cleansing wounds, reducing bacterial load, and removing loose material. The U.S. market for wound cleansers is substantial, with an annual size exceeding $200 million USD, indicating a significant opportunity for Kane Biotech to enhance its market presence and impact stakeholders positively.

Kane Biotech Exceeds Enrollment Target in U.S. Studies for revyve® Wound Care Products

Kane Biotech has successfully completed enrollment for its U.S. Case Series Studies of the revyve® Antimicrobial Wound Gel and Spray, surpassing their target with 28 participants. This development highlights the growing interest from clinicians and patients in the U.S., potentially enhancing the company’s position in the wound care market by demonstrating the effectiveness of their products in treating challenging wounds and burns.

Kane Biotech to Showcase revyve® Clinical Data at SAWC Fall Conference

Kane Biotech announced that its Interim CEO, Dr. Robert Huizinga, will present clinical data on their revyve Antimicrobial Wound Gel at the Symposium on Advanced Wound Care Fall Conference. The data highlights the effectiveness of revyve in healing complex wounds, including a two-year-old non-healing sacral ulcer and a venous leg ulcer, demonstrating significant pain reduction and wound size decrease. This presentation underscores Kane Biotech’s commitment to advancing wound care solutions and may enhance its market position by attracting potential US distributors.

Kane Biotech Reports Q2 2025 Financials Amid Strategic Restructuring

Kane Biotech reported a significant drop in revenue for the second quarter of 2025 compared to the same period in 2024, primarily due to the sale of its animal health business. Despite the financial challenges, the company is actively engaging with wound care specialists in the U.S., presenting promising preclinical data, and restructuring its board to strengthen strategic capabilities, aiming to enhance the commercialization of its revyve portfolio and drive long-term shareholder value.